Lv12
60 积分 2025-10-08 加入
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
3天前
已完结
Pharmacological treatment for metabolic dysfunction–associated steatotic liver disease and related disorders: Current and emerging therapeutic options
3天前
已完结
Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial
30天前
已完结
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial
30天前
已完结
皖公网安备34019202002308
